Download

Poster
Web banner
Leaflet

Invited Speakers

prev next
  • Martina U. Muckenthaler PL01 Regulation of iron metabolism University of Heidelberg, Germany CV Abstract
  • Marcel van den Brink PL02 The role of the intestinal microbiome in cancer immunotherapy Memorial Sloan Kettering Cancer Center, USA CV Abstract
  • Toshio Suda PL03 Recent advance in the hematopoietic stem cell research National University of Singapore, Singapore CV Abstract
  • Taeghwan Hyeon PS01 What can Nano do for Medicine? Seoul National University, Korea CV Abstract
  • Chiaki Nakaseko JS01-1 POEMS syndrome: advances in molecular pathophysiology and treatment International University of Health and Welfare School of Medicine, Japan CV Abstract
  • Jin Seok Kim JS01-2 Updates on POEMS syndrome in Korea Yonsei University College of Medicine, Korea CV Abstract
  • Hiroshi Handa JS01-3 Therapeutic approach of Waldenström's macroglobulinemia in Japan Gunma University, Japan CV Abstract
  • Hosup Lee JS01-4 Clinical researches on Waldenström's macroglobulinemia in Korea Kosin University College of Medicine, Korea CV Abstract
  • Katy Rezvani JS02-1 NK cells: next generation cell therapies for cancer The University of Texas MD Anderson Cancer Center, USA CV Abstract
  • Seok Jin Kim JS02-2 Treatment of extranodal NK/T-cell lymphoma: Korean Lymphoma Working Party experience Sungkyunkwan University School of Medicine, Korea CV Abstract
  • John DiPersio JS02-3 CART for the treatment of T cell malignancies Washington University School of Medicine, USA CV Abstract
  • Deok-Hwan Yang JS02-4 Treatment of peripheral T-cell lymphoma: Korean Lymphoma Working Party experience Chonnam National University Medical School, Korea CV Abstract
  • Uwe Platzbecker JS03-1 Novel approaches in MDS Leipzig University Hospital, Germany CV Abstract
  • June-Won Cheong JS03-2 Treatment of MDS: Korean AML/MDS working party experience Yonsei University College of Medicine, Korea CV Abstract
  • Lionel Adès JS03-3 Standard management of MDS Hopital Saint Louis and Paris University, France CV Abstract
  • Yoo-Jin Kim JS03-4 Genetic alterations in myelodysplastic neoplasms The Catholic University of Korea, Korea CV Abstract
  • Nguyen Thi Thao JS04-1 Overview of AA diagnosis and treatment in NIHBT, VietNam National Institute of Hematology and Blood Transfusion, Vietnam CV Abstract
  • Lalita Norasetthada JS04-2 The incidence and real-world outcome of aplastic anemia in Thailand Chiang Mai University, Thailand CV Abstract
  • Jun Ho Jang JS04-3 Role of TPO receptor agonists in aplastic anemia treatment Samsung Medical Center, Korea CV Abstract
  • Mahmood A. Chowdhury JS05-1 Overview of thalassaemia and hemoglobinopathies in Bangladesh Chattogram Maa-O-Shishu Hospital Medical College, Bangladesh CV Abstract
  • Chean Sophal JS05-2 Current situation of thalassemia care in Cambodia National Pediatric Hospital, Cambodia CV Abstract
  • Heewon Chueh JS05-3 Epidemiology and diagnosis of hemolytic anemia in Korea Dong-A University College of Medicine, Korea CV Abstract
  • Geoffrey McDermott CS01-1 Accelerate breakthroughs in hematology with single cell sequencing 10x Genomics, Inc., USA CV Abstract
  • Tabe Yoko CS01-2 AI technology in the field of blood disease Juntendo University, Japan CV Abstract
  • Gina Sun CS01-3 Discover the unique power of using droplet digital PCR (ddPCR) for hematology-oncology applications Bio-Rad Laboratories, USA CV Abstract
  • Yongkeun Park CS01-4 Holotomography and artificial intelligence: label-free 3D imaging, classification, and inference Tomocube Inc., Korea CV Abstract
  • Bong-Seog Kim CS02-1 A Phase 1a Study of BR101801, PI3Kγδ and DNA PK Triple Inhibitor, in Adult Patients with Advanced Hematologic Malignancies Boryung Co. Ltd., Korea CV Abstract
  • Woorim Kang CS02-2 The gut microbiome as a novel predictive biomarker and therapeutic target in lymphoma patients CJ Bioscience Inc., Korea CV Abstract
  • Jonghwa Won CS02-3 Bispecific antibody : ABL Bio ABL Bio Inc., Korea CV Abstract
  • Sung-Min Ahn CS02-4 KF1601, a novel orally bioavailable inhibitor of Bcr-Abl T315I, without thrombotic microangiopathy ImmunoForge Inc., Korea CV Abstract
  • Kelly Walkovich SS01-1 How to diagnosis and treat neutropenia in childhood University of Michigan, USA CV Abstract
  • Keon Hee Yoo SS01-2 Updates in the treatment of pediatric relapsed/refractory acute myeloid leukemia Sungkyunkwan University School of Medicine, Korea CV Abstract
  • Micheal Verneris SS01-3 Use of chimeric antigen receptor (CAR) expressing T cells for acute lymphoblastic leukemia (ALL) Children’s Hospital Colorado, USA CV Abstract
  • Ralf Küppers SS02-1 Pathogenesis of hodgkin lymphoma University of Duisburg-Essen, Germany CV Abstract
  • Natalie S Grover SS02-2 Emerging cellular therapy in HL The University of North Carolina at Chapel Hill, USA CV Abstract
  • Hyeon-Seok Eom SS02-3 Novel treatment of relapsed/refractory hodgkin lymphoma National Cancer Center, Korea CV Abstract
  • Emma M. Groarke SS03-1 Aplastic anemia: Current management considerations National Institutes of Health, USA CV Abstract
  • Jaroslaw P. Maciejewski SS03-2 Clinical and molecular factors of clonal evolution in aplastic anemia Cleveland Clinic, USA CV Abstract
  • Jae Wook Lee SS03-3 Non-transplant therapy for pediatric aplastic anemia The Catholic University of Korea, Korea CV Abstract
  • Sandro Rossetti SS04-1 Diagnosis and treatment of TA-TMA; Current challenge and future strategies Hospital Alexion Pharmaceuticals, Inc., USA CV
  • Kathleen Freson SS04-2 Genetics of inherited thrombocytopenia University of Leuven, Belgium CV Abstract
  • Hyun Kyung Kim SS04-3 Advances on pathogenesis and diagnosis of TTP Seoul National University College of Medicine, Korea CV Abstract
  • Roni Shouval SS05-1 Artificial intelligence in hematology: basic concepts Memorial Sloan kettering Cancer Center, USA CV Abstract
  • Valeria Visconte SS05-2 How ML deepens our understanding of hematologic malignancies? Cleveland Clinic, USA CV Abstract
  • Jongmun Choi SS05-3 Pitfalls of AI for medical application Green Cross Genome, Korea CV Abstract
  • Niels van de Donk SS06-1 Identification of high-risk multiple myeloma Amsterdam University Medical Center, The Netherlands CV Abstract
  • Sung-Hoon Jung SS06-2 Updated diagnosis and treatment of plasma cell leukemia Chonnam National University Hwasun Hospital, Korea CV Abstract
  • Moshe Gatt SS06-3 Safety and efficacy of locally produced novel BCMA CART cells for relapsed/refractory multiple myeloma and al amyloidosis The Hebrew University of Jerusalem, Israel CV Abstract
  • Yvonne Chen SS07-1 Engineering next-generation T cells for cancer immunotherapy University of California, USA CV Abstract
  • Hyoung Jin Kang SS07-2 Development of CAR-T therapy for acute lymphoblastic leukemia Seoul National University College of Medicine, Korea CV Abstract
  • Hiroshi Fujiwara SS07-3 Updates on the latest developments in CAR-T therapies Mie University, Japan CV Abstract
  • Jill Johnsen SS08-1 Genotyping of hemophilia, why we need it and how we do? Division of Hematology University of Washington, USA CV Abstract
  • Jung Woo Han SS08-2 Value of national cohort registry data of hemophilia Yonsei University College of Medicine, Korea CV Abstract
  • Sang Hyuk Park SS08-3 Essentials of laboratory issues in Emicizumab Ulsan University Hospital CV Abstract
  • Naval Daver SS09-1 Immune checkpoint inhibition for AML ; CD47 blockade and beyond MD Anderson Cancer Center, USA CV
  • Miriam Y Kim SS09-2 Determining the barriers to successful CAR T cell therapy for AML University of Washington, USA CV Abstract
  • Byung Sik Cho SS09-3 Adoptive T cell transfer of three universal tumor associated antigens-specific T cells for the treatment of AML The Catholic University of Korea, Korea CV Abstract
  • Aly Karsan SS10-1 A transcriptomic approach to clinical diagnosis, prognosis and therapy selection in AML University of British Columbia, Canada CV Abstract
  • Sunghoon Kwon SS10-2 Whole genome sequencing of fluorescence in situ hybridized cells in hematologic malignancies using SLACS Seoul National University, Korea CV Abstract
  • Alexander Hoischen SS10-3 Next generation cytogenetics – optical mapping for comprehensive structural variant detection in hematological malignancies and beyond Radboud University Medical Center, The Netherlands CV Abstract
  • Iwijn De Vlaminck SS11-1 Cell-free DNA profiling for monitoring of complications of hematopoietic cell transplantation Cornell University, USA CV Abstract
  • Charles Gawad SS11-2 Microbial cell-free DNA sequencing to predict bloodstream infection in pediatric cancer patients Stanford University, USA CV Abstract
  • Seung-Tae Lee SS11-3 Clinical applications of circulating tumor DNA analysis in lymphoma Yonsei University College of Medicine, Korea CV Abstract
  • Robin Foa SS12-1 Are we moving towards a chemo- and transplant-free management of Ph-positive adult ALL? Sapienza University of Rome, Italy CV Abstract
  • Saar I Gill SS12-2 Development of more-effective CAR T-cell therapy for ALL University of Pennsylvania School of Medicine, USA CV Abstract
  • Jae-Ho Yoon SS12-3 Overcoming high-risk features in adult ALL patients The Catholic University of Korea, Korea CV Abstract
  • William J. Greenleaf SS13-1 Single cell HSPC map Stanford University, USA CV Abstract
  • Kyung-Rok Yu SS13-2 Humanized mouse and non-human primate: Animal models for hematopoietic stem cell research Seoul National University, Korea CV Abstract
  • Xinxin Huang SS13-3 What we know about HSC homing? Fudan University, China CV Abstract
  • Richard Rosenquist SS14-1 Translating scientific advances in CLL Karolinska Institute, Sweden CV Abstract
  • Jennifer R. Brown SS14-2 Patient selection for time limited versus continued therapy Dana-Farber Cancer Institute, USA CV Abstract
  • Ki-Seong Eom SS14-3 MRD monitoring in CLL Patients The Catholic University of Korea, Korea CV Abstract
  • Eun-Ji Choi ES01-1 Asciminib: the first-in-class allosteric inhibitor of BCR/ABL1 kinase University of Ulsan College of Medicine, Korea CV Abstract
  • Jieun Uhm ES01-2 Treatment after failure of frontline therapy of CML-CP including allo-HSCT Hanyang University College of Medicine, Korea CV
  • Jae Joon Han ES01-3 Update on treatment free remission Kyung Hee University College of Medicine, Korea CV Abstract
  • Youngwoo Jeon ES02-1 Intravascular B-cell lymphoma The Catholic University of Korea, Korea CV
  • Jae-Cheol Jo ES02-2 T-large granular lymphocytic leukemia University of Ulsan College of Medicine, Korea CV Abstract
  • Jeong-Ok Lee ES02-3 Lymphomatoid granulomatosis Seoul National University Bundang Hospital, Korea CV
  • Hyewon Lee ES03-1 Sezary syndrome and mycosis fungoides National Cancer Center, Korea CV Abstract
  • Hyun Jung Lee ES03-2 Systemic mastocytosis Kyung Hee University College of Medicine, Korea CV Abstract
  • Yoo Jin Lee ES03-3 Plasmacytoid dendritic cell neoplasm University of Ulsan College of Medicine, Korea CV Abstract
  • Dong Wook Jekarl ES04-1 Transfusion support for HSCT The Catholic University of Korea, Korea CV Abstract
  • Dae-Hyun Ko ES04-2 Evidence based transfusion threshold University of Ulsan College of Medicine, Korea CV Abstract
  • Eun Jung Baek ES04-3 Current status of manufactured blood cells Hanyang University College of Medicine, Korea CV Abstract
  • Ja Min Byun ES05-1 Setting up the facility for CAR T cell therapy Seoul National University College of Medicine, Korea CV Abstract
  • Jong-Seo Lee ES05-2 Technical aspect of manufacturing CAR T cell product AbClon Inc., Korea CV
  • Jae Won Yoo ES05-3 Managing adverse events of CAR T cell therapy The Catholic University of Korea, Korea CV Abstract
  • Junshik Hong ES06-1 Prognostication in MPNs (including mutation abnormalities) Seoul National University Hospital, Korea CV Abstract
  • Sung-Eun Lee ES06-2 Novel Therapeutics for MF (including cyotpenic myelofibrosis) The Catholic University of Korea, Korea CV Abstract
  • Seugyun Yoon ES06-3 Novel Therapeutics for ET/PV Soonchunhyang University Seoul Hospital, Korea CV Abstract
  • Andreas Hocchaus ASCIMINIB, new paradigm treatment option in CML for patients who were previously treated with 2 or more TKIs Jena University Hospital, Germany CV Abstract
  • Georg Lenz Unmet need in 1L DLBCL and POLARIX trial University Hospital in Münster, Germany CV Abstract
  • Kevin Song Maintenance treatment post autotransplant for multiple myeloma Vancouver General Hospital, Canada CV Abstract
  • Kohei Hosokawa Recent advances in the pathogenesis and treatment of aplastic anemia Kanazawa University, Japan CV Abstract
  • Martin Bornhaeuser Value of intensive therapy in high-risk AML University Hospital Carl Gustav Carus Dresden, Germany CV Abstract
  • Paolo Ghia When and whom to start treatment of CLL patients and how to optimally manage CLL patients with Imbruvica IRCCS Ospedale San Raffaele, Italy CV Abstract
Organized by
Supported by

Sponsored by